Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia

NCT06802718 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

96

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Interferon

Sponsor

Peking University People's Hospital